Evidence Hub

Severe Cutaneous Adverse Reactions Associated With Newer-Generation Antiseizure Medications: A Real-World Pharmacovigilance Study Based on FAERS and JADER

You L, Zhang D, Cheng Z, Qi Y, Qian R

CNS neuroscience & therapeutics, 2026

Abstract

Background: Severe cutaneous adverse reactions (SCARs) are rare but potentially fatal immune-mediated toxicities associated with antiseizure medications (ASMs). Phenotype-resolved post-marketing safety profiles for newer-generation ASMs have not been comprehensively characterized across pharmacovigilance systems.

Methods: A cross-database disproportionality analysis was conducted using FAERS and JADER (January 2004-September 2025). Twenty-two newer-generation ASMs coded as primary-suspect drugs were included; outcomes were the four SCAR phenotypes (Stevens-Johnson syndrome, SJS; toxic epidermal necrolysis, TEN; drug reaction with eosinophilia and systemic symptoms, DRESS; acute generalized exanthematous pustulosis, AGEP) defined using MedDRA preferred terms. Signals were evaluated using reporting odds ratios (RORs) and Bayesian information component metrics. Time-to-onset (TTO) was characterized by Weibull modeling with confidence-interval-based failure-pattern classification and Kaplan-Meier analysis. Pre-specified sensitivity analyses excluded reports with concomitant valproic acid or other SCAR-inducing co-medications, applied multivariate logistic regression, and restricted FAERS reports to healthcare professionals.

Results: In total, 10,073 SCAR reports were included (SJS, 3776; TEN, 1762; DRESS, 4298; AGEP, 237). Lamotrigine and zonisamide showed the strongest, most reproducible associations across SJS/TEN/DRESS (FAERS RORs for lamotrigine, 35.60/22.35/27.30;…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free